covid-19 vaccine

J&J selects Emergent BioSolutions for Covid-19 vaccine manufacturing

Reading now: 567
www.pharmaceutical-technology.com

Johnson & Johnson (J&J) subsidiary Janssen Pharmaceutical has signed an agreement with Emergent BioSolutions for manufacturing services for its lead investigational Covid-19 vaccine candidate.

The vaccine programme builds on Janssen’s AdVac and PER.C6 technologies. Under the agreement, worth around $135m, Emergent will offer drug substance manufacturing services using its molecule-to-market CDMO offering.

The services will support investments from J&J starting this year. Emergent will reserve some large-scale manufacturing capacity to prepare for commercial manufacturing of the adenovirus-based Covid-19 vaccine beginning next year.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA